Interestingly, while anti-IL5 therapy (using Mepolizumab, Reslizumab, or Benralizumab) in patients with asthma decreased their BMI (103), blood hyper-eosinophilia was associated with a decreased risk of T2D in an adult cohort composed of both women and men in China (104). The gene discussed is IL5; the disease is type 2 diabetes mellitus.